Status:
UNKNOWN
Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland
Lead Sponsor:
Cardiovascular Research Institute Dublin
Conditions:
SARS-CoV Infection
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
SETANTA study will investigate the incidence of cardiac abnormalities as assessed by cardiac magnetic resonance imaging in unselected patients after acute SARS-CoV-2 infection and correlation with imm...
Detailed Description
Approximately 100 participants from primary care will be enrolled via General Practitioner (GP) or Primary Care Centers in Dublin. A patient information sheet (PIS) will be made accessible to particip...
Eligibility Criteria
Inclusion
- Patients 18 years or older
- Written informed consent
- Recent COVID-19 infection ≥ 6 weeks and ≤ 12 months before enrolment, as evidenced by positive reverse-transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 swab
Exclusion
- Prior history of myocarditis or ischemic heart disease
- General contraindications for Magnetic Resonance Imaging e.g. Magnetic Resonance unsafe pacemaker, devices, implants etc.
- Contraindication to gadolinium (estimated glomerular filtration rate \<30 ml/min)
- Contraindication to Regadenoson, including cardiac conduction disease, asthma, seizures, pregnancy or breast-feeding
- Inability to provide written informed consent, to fill out the safety questionnaire, or to fully cooperate with the scan and breath holds
- Insufficient Cardiac Magnetic Resonance image quality
Key Trial Info
Start Date :
February 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 22 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04823182
Start Date
February 16 2021
End Date
September 22 2022
Last Update
September 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiovascular Research Institute Dublin
Dublin, Ireland, D07 KWR1